SlideShare a Scribd company logo
HIV Highlights From Seattle
   CCO Independent Conference Coverage
   of the 2012 Conference on Retroviruses and Opportunistic Infections*


   March 5-8, 2012
   Seattle, Washington
   *CCO is an independent medical education company that
   provides state-of-the-art medical information to healthcare
   professionals through conference coverage and other
   educational programs.




This program is supported by educational grants from




 Originally posted 3/20/2012 at clinicaloptions.com/ss/Seattle2012
HIV Highlights From Seattle
clinicaloptions.com/hiv




 About These Slides
  Users are encouraged to use these slides in their own
   noncommercial presentations, but we ask that content
   and attribution not be changed. Users are asked to honor
   this intent
  This abbreviated slideset was posted to SlideShare to
   publicize the availability of the full slideset. These slides
   may not be published or posted online without permission
   from CCO (email permissions@clinicaloptions.com)
Disclaimer
The materials published on the Clinical Care Options Web site reflect the views of the authors of the
CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing
educational grants. The materials may discuss uses and dosages for therapeutic products that have not
been approved by the United States Food and Drug Administration. A qualified healthcare professional
should be consulted before using any therapeutic product discussed. Readers should verify all information
and data before treating patients or using any therapies described in these materials.
HIV Highlights From Seattle
clinicaloptions.com/hiv




 Faculty
 Joseph J. Eron, Jr., MD               Kimberly Y. Smith, MD, MPH
 Professor of Medicine and             Associate Professor of Medicine
 Epidemiology                          Division of Infectious Diseases
 University of North Carolina          Rush University Medical Center
 School of Medicine                    Chicago, Illinois
 Director, AIDS Clinical Trials Unit
 University of North Carolina
 Chapel Hill, North Carolina
HIV Highlights From Seattle
clinicaloptions.com/hiv




 Faculty Disclosures
 Joseph J. Eron, Jr., MD, has disclosed that he has received
 grants for research support from Bristol-Myers Squibb,
 GlaxoSmithKline/ViiV, Merck, Taimed, and Tobira; has
 served as a consultant for Argos, Avexa, Bristol-Myers
 Squibb, Chimerix, Gilead Sciences, GlaxoSmithKline/ViiV,
 Inhibitex, Kainos Pharmaceutical, LabCorp, Merck, Myriad,
 Pfizer, Tibotec, Tobira, and Virco Laboratories; and has
 served on data and safety monitoring boards for
 Tibotec/Janssen and Vertex.
 Kimberly Y. Smith, MD, MPH, has disclosed that she has
 served as a consultant for Bristol-Myers Squibb, Gilead
 Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV.
Please review the slide notes for
 a complete discussion of each
    study by expert faculty
  Joseph J. Eron, Jr., MD, and
  Kimberly Y. Smith, MD, MPH
New Agents
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Elvitegravir/Cobicistat/TDF/FTC vs
 EFV/TDF/FTC in Treatment-Naive Patients
     Multicenter, randomized, double-blinded, active-controlled phase III study


                                                 Wk 48                               Planned follow-up
                       Stratified by         primary analysis                            to Wk 192
                  baseline HIV-1 RNA
                > or ≤ 100,000 copies/mL


                                               Elvitegravir/Cobicistat/TDF/FTC QD
                                                   + EFV/TDF/FTC placebo QD
         HIV-infected                                        (n = 348)
 treatment-naive patients with
HIV-1 RNA ≥ 5000 copies/mL,
     any CD4+ cell count,
      CLCR ≥ 70 mL/min
                                                          EFV/TDF/FTC QD
           (N = 700)                       + Elvitegravir/Cobicistat/TDF/FTC placebo QD
                                                              (n = 352)


Sax P, et al. CROI 2012. Abstract 101.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Elvitegravir/Cobicistat Regimen
 Noninferior to EFV Regimen at Wk 48
               100        88                90                  84               EVG/COBI/FTC/TDF
                               84                 85                  82         (n = 348)
                80
                                                                                 EFV/FTC/TDF
                60                                                               (n = 352)
                40
                20
                  0
                          Overall          HIV-1 RNA          HIV-1 RNA
                                         ≤ 100,000 c/mL     > 100,000 c/mL
     Greater CD4+ count increase with EVG/COBI vs EFV: 239 vs 206 cells/mm3 (P = .009)
     Among pts with confirmed virologic failure or rebound, resistance detected in 8/14 pts in
      EVG/COBI arm vs 8/17 patients in EFV arm
        –   Primary integrase mutations and primary NNRTI mutations observed in 7 and 8 patients in
            EVG/COBI and EFV arms, respectively
        –   All 8 pts in EVG/COBI arm had M184V/I mutation vs 2 pts in EFV arm; 3 and 2 had K65R,
            respectively
Sax P, et al. CROI 2012. Abstract 101.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Safety of Elvitegravir/Cobicistat Regimen
 vs EFV Regimen
  Significantly greater incidence of nausea with EVG/COBI regimen

  Significantly greater incidence of sleep disturbance, dizziness, rash
   with EFV regimen
  1.4% of patients discontinued EVG/COBI regimen due to renal
   abnormalities vs no patients on EFV regimen
       – Significantly greater increase in median serum creatinine from baseline to
         Wk 48 in EVG/COBI group: 0.14 vs 0.01 mg/dL (P < .001)

       – Majority of increase in serum creatinine clearance occurred within 2 wks of
         starting treatment and progressed minimally over time

  Significantly greater increases in total, LDL, and HDL cholesterol from
   baseline to Wk 48 in EFV vs EVG/COBI groups (all P ≤ .001)
Sax P, et al. CROI 2012. Abstract 101.
HIV Highlights From Seattle
  clinicaloptions.com/hiv



   Elvitegravir/Cobicistat/TDF/FTC vs
   ATV/RTV + TDF/FTC in Tx-Naive Patients
       Multicenter, randomized, double-blinded, active-controlled phase III study

                                                   Wk 48                        Planned follow-up
                       Stratified by
                                               primary analysis                     to Wk 192
                  baseline HIV-1 RNA
                > or ≤ 100,000 copies/mL

                                               Elvitegravir/Cobicistat/TDF/FTC QD
        HIV-infected                           + ATV/RTV + FTC/TDF placebo QD
  treatment-naive patients,                                  (n = 353)
HIV-1 RNA ≥ 5000 copies/mL,
    any CD4+ cell count,
      CLCR ≥ 70 mL/min
                                                    ATV/RTV + TDF/FTC QD
            (N = 708)                    + Elvitegravir/Cobicistat/TDF/FTC placebo QD
                                                            (n = 355)


  DeJesus E, et al. CROI 2012. Abstract 627.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Elvitegravir/Cobicistat Regimen
 Noninferior to ATV/RTV Regimen at Wk 48
               100        90                 93   90                    EVG/COBI/FTC/TDF
                               87                         85   82       (n = 353)
                80
                                                                        ATV/RTV + FTC/TDF
                60                                                      (n = 355)
                40
                20
                  0
                          Overall       HIV-1 RNA        HIV-1 RNA
                                      ≤ 100,000 c/mL   > 100,000 c/mL

     Similar CD4+ cell count increases in both study arms at Wk 48
     Among pts with confirmed virologic failure or rebound, resistance detected in
      5/12 pts in EVG/COBI arm vs 0/8 pts in ATV/RTV arm
        – 4/5 pts in EVG/COBI arm had M184V/I mutation; 4 had primary integrase mutations

DeJesus E, et al. CROI 2012. Abstract 627.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Safety of Elvitegravir/Cobicistat Regimen
 vs ATV/RTV Regimen
  Similar rates of grade 3/4 adverse events between arms: 13% in EVG/
   COBI and 14% in ATV/RTV arm
        – Most common adverse events: diarrhea, nausea

  Grade 3/4 hyperbilirubinemia more common in ATV/RTV group:
   58% vs 1%
  Significantly greater increase in median serum creatinine from
   baseline to Wk 48 in EVG/COBI group: 0.12 vs 0.08 mg/dL (P < .001)
        – Majority of increase in serum creatinine clearance occurred within 2 wks of
          starting treatment and progressed minimally over time
  Significantly greater increase in median triglycerides from baseline to
   Wk 48 in ATV/RTV group: 23 vs 8 mg/dL (P = .006); otherwise no
   difference in lipid values
DeJesus E, et al. CROI 2012. Abstract 627.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 SPRING-1: Phase IIb Trial of Dolutegravir
 vs Efavirenz in Tx-Naive Patients
                                      100                                                                            88
      < 50 copies/mL (TLOVR) (%)[1]




                                                                                                                     79
        Patients With HIV-1 RNA




                                                                                                                     78
                                       80                                                                            72

                                       60

                                       40                                            DTG 10 mg QD (n = 53)
                                                                                     DTG 25 mg QD (n = 51)
                                                                                     DTG 50 mg QD (n = 51)
                                       20
                                                                                     EFV 600 mg (n = 50)

                                         0
                                             BL 4 8 1216 20 24    32   40      48    60       72       84       96
                                                                                Wk
     Comparable efficacy among arms
     No cases of virologic failure in 50-mg arm
     Minimal variations in serum creatinine observed across treatment arms
              –                       Alterations did not progress over time
              –                       Previous study showed DTG had no effect on glomerular filtration rate by iohexol clearance[2]
1. Stellbrink HJ, et al. CROI 2012. Abstract 102LB. 2. Koteff J, et al. ICAAC 2011. Abstract A1-1728.
HIV Highlights From Seattle
 clinicaloptions.com/hiv



  GS-7340: Antiviral Activity of Novel
  Prodrug of Tenofovir
      Lower TDF plasma concentrations, higher intracellular concentrations obtained with
       GS-7340 vs TDF
         –   Hypothesized that this may result in greater efficacy, reduced toxicity
      Previous study evaluated higher doses of GS-7340: 50 mg and 150 mg[1]             10 days

                                                                    TDF 300 mg QD
                                                                        (n = 6)
          HIV-infected
                                                                  GS-7340 8 mg QD
treatment-naive or -experienced
   patients with no genotypic                                          (n = 9)
       resistance to TDF,                                         GS-7340 25 mg QD
 HIV-1 RNA ≥ 2000 copies/mL,                                           (n = 8)
  CD4+ count ≥ 200 cells/mm3[2]
                                                                  GS-7340 40 mg QD
               (N = 38)                                                (n = 8)
                                                                 GS-7340 Placebo QD
                                                                       (n = 7)
 1. Markowitz M, et al. CROI 2011. Abstract 152LB. 2. Ruane PJ, et al. CROI 2012. Abstract 103.
HIV Highlights From Seattle
clinicaloptions.com/hiv



 Greater Antiviral Activity of GS-7340 25
 mg and 40 mg vs TDF
                               Dosing
                     0.5
                                                        Placebo (n = 7)
                     0.0                                TDF 300 mg (n = 6)
                                                        GS-7340 8 mg (n = 9)
                    -0.5                                GS-7340 25 mg (n = 8)
                                                        GS-7340 40 mg (n = 8)
                    -1.0

                    -1.5

                    -2.0
                           0            10         20
                                             Day

  Higher intracellular tenofovir diphosphate levels and lower
   circulating plasma tenofovir levels with GS-7340 vs TDF
Ruane PJ, et al. CROI 2012. Abstract 103.
For the rest of this presentation download
the full PowerPoint slideset for self-study
or use in your own educational presentations
at: clinicaloptions.com/ss/seattle2012

Go Online for More CCO Coverage of CROI 2012:

Capsule Summaries of key data from the meeting &
CME-certified slideset incorporating a discussion
among 2 expert faculty exploring the clinical implications
of each study


More ways to connect with CCO:

More Related Content

What's hot

Zoulim fz traitement hépatite b 2015 du
Zoulim  fz traitement hépatite b 2015 duZoulim  fz traitement hépatite b 2015 du
Zoulim fz traitement hépatite b 2015 du
odeckmyn
 
New Data on Resistance to DAAs and Implications for Therapy.2015
New Data on Resistance to DAAs and Implications for Therapy.2015New Data on Resistance to DAAs and Implications for Therapy.2015
New Data on Resistance to DAAs and Implications for Therapy.2015
hivlifeinfo
 
Zoulim2 traitement hépatite b 2016 d uv2
Zoulim2  traitement hépatite b 2016 d uv2Zoulim2  traitement hépatite b 2016 d uv2
Zoulim2 traitement hépatite b 2016 d uv2
odeckmyn
 
Castera élastométrie:pbh du16
Castera  élastométrie:pbh du16Castera  élastométrie:pbh du16
Castera élastométrie:pbh du16
odeckmyn
 
Clinical Impact of New Data From AASLD 2015
Clinical Impact of New Data From AASLD 2015Clinical Impact of New Data From AASLD 2015
Clinical Impact of New Data From AASLD 2015
hivlifeinfo
 
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
hivlifeinfo
 
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
hivlifeinfo
 
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
hivlifeinfo
 
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
hivlifeinfo
 
Highlights of AIDS 2016
Highlights of AIDS 2016Highlights of AIDS 2016
Highlights of AIDS 2016
hivlifeinfo
 
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
hivlifeinfo
 
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
hivlifeinfo
 
Confronting the Challenges of HIV Care in an Aging Population.2019
Confronting the Challenges of HIV Care in an Aging Population.2019Confronting the Challenges of HIV Care in an Aging Population.2019
Confronting the Challenges of HIV Care in an Aging Population.2019
hivlifeinfo
 
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
hivlifeinfo
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
hivlifeinfo
 
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
hivlifeinfo
 
First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013
Hivlife Info
 
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
hivlifeinfo
 
Classical Hodgkin’s lymphoma
Classical Hodgkin’s lymphomaClassical Hodgkin’s lymphoma
Classical Hodgkin’s lymphoma
Ankit Raiyani
 
Benhamou co infection
Benhamou    co infectionBenhamou    co infection
Benhamou co infection
odeckmyn
 

What's hot (20)

Zoulim fz traitement hépatite b 2015 du
Zoulim  fz traitement hépatite b 2015 duZoulim  fz traitement hépatite b 2015 du
Zoulim fz traitement hépatite b 2015 du
 
New Data on Resistance to DAAs and Implications for Therapy.2015
New Data on Resistance to DAAs and Implications for Therapy.2015New Data on Resistance to DAAs and Implications for Therapy.2015
New Data on Resistance to DAAs and Implications for Therapy.2015
 
Zoulim2 traitement hépatite b 2016 d uv2
Zoulim2  traitement hépatite b 2016 d uv2Zoulim2  traitement hépatite b 2016 d uv2
Zoulim2 traitement hépatite b 2016 d uv2
 
Castera élastométrie:pbh du16
Castera  élastométrie:pbh du16Castera  élastométrie:pbh du16
Castera élastométrie:pbh du16
 
Clinical Impact of New Data From AASLD 2015
Clinical Impact of New Data From AASLD 2015Clinical Impact of New Data From AASLD 2015
Clinical Impact of New Data From AASLD 2015
 
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
 
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
АРТ в 2016-2017 гг: неизменная потребность в индивидуализации лечения для улу...
 
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive ...
 
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
HIV Alert: Best Practices in ART Following Recent Drug Approvals.2016
 
Highlights of AIDS 2016
Highlights of AIDS 2016Highlights of AIDS 2016
Highlights of AIDS 2016
 
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
HIV Alert :Updating Your Practice Based on New Guideline Recommendations.2016
 
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
Ключевые решения в лечении ВИЧ: оптимизация стратегии лечения для пациентов с...
 
Confronting the Challenges of HIV Care in an Aging Population.2019
Confronting the Challenges of HIV Care in an Aging Population.2019Confronting the Challenges of HIV Care in an Aging Population.2019
Confronting the Challenges of HIV Care in an Aging Population.2019
 
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
 
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
 
First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013
 
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
Managing Treatment-Experienced Patients With Multidrug Resistance-Emerging Op...
 
Classical Hodgkin’s lymphoma
Classical Hodgkin’s lymphomaClassical Hodgkin’s lymphoma
Classical Hodgkin’s lymphoma
 
Benhamou co infection
Benhamou    co infectionBenhamou    co infection
Benhamou co infection
 

Viewers also liked

Workshop with the Experts: Colorectal Cancer Series
Workshop with the Experts: Colorectal Cancer SeriesWorkshop with the Experts: Colorectal Cancer Series
Workshop with the Experts: Colorectal Cancer Series
Clinical Care Options
 
الكتاب المقدس يتكلم عن الايمان فيقول
الكتاب المقدس يتكلم عن الايمان فيقولالكتاب المقدس يتكلم عن الايمان فيقول
الكتاب المقدس يتكلم عن الايمان فيقول
Ibrahimia Church Ftriends
 
Roman Geo
Roman GeoRoman Geo
Roman Geo
ssclasstorremar
 
اسس علم الاجتماع
اسس علم الاجتماعاسس علم الاجتماع
اسس علم الاجتماع
Ibrahimia Church Ftriends
 
2 1 farewell sermon
2 1 farewell sermon2 1 farewell sermon
2 1 farewell sermon
ssclasstorremar
 
GoPro - The Surf Fanatic
GoPro - The Surf FanaticGoPro - The Surf Fanatic
GoPro - The Surf Fanatic
Heiko Hartsuijker
 
Second Quarter 2013 Investor Presentation
Second Quarter 2013 Investor PresentationSecond Quarter 2013 Investor Presentation
Second Quarter 2013 Investor Presentation
CNOServices
 
Reebok the sport of fitness has arrived
Reebok   the sport of fitness has arrivedReebok   the sport of fitness has arrived
Reebok the sport of fitness has arrived
Heiko Hartsuijker
 
Linking words
Linking wordsLinking words
Linking words
Kathryn Chin
 
Decline of the Roman Republic
Decline of the Roman RepublicDecline of the Roman Republic
Decline of the Roman Republic
ssclasstorremar
 
Emperor penguins in_antarctica
Emperor penguins in_antarcticaEmperor penguins in_antarctica
Emperor penguins in_antarctica
barbcos
 
Madkour and zinhome
Madkour and zinhomeMadkour and zinhome
Madkour and zinhome
Al Baha University
 
الطريق اتجاه واحد النبوءه - الحقيقه - One way -
الطريق اتجاه واحد   النبوءه - الحقيقه - One way -الطريق اتجاه واحد   النبوءه - الحقيقه - One way -
الطريق اتجاه واحد النبوءه - الحقيقه - One way -
Ibrahimia Church Ftriends
 
женщины
женщиныженщины

Viewers also liked (15)

Workshop with the Experts: Colorectal Cancer Series
Workshop with the Experts: Colorectal Cancer SeriesWorkshop with the Experts: Colorectal Cancer Series
Workshop with the Experts: Colorectal Cancer Series
 
الكتاب المقدس يتكلم عن الايمان فيقول
الكتاب المقدس يتكلم عن الايمان فيقولالكتاب المقدس يتكلم عن الايمان فيقول
الكتاب المقدس يتكلم عن الايمان فيقول
 
Roman Geo
Roman GeoRoman Geo
Roman Geo
 
اسس علم الاجتماع
اسس علم الاجتماعاسس علم الاجتماع
اسس علم الاجتماع
 
2 1 farewell sermon
2 1 farewell sermon2 1 farewell sermon
2 1 farewell sermon
 
GoPro - The Surf Fanatic
GoPro - The Surf FanaticGoPro - The Surf Fanatic
GoPro - The Surf Fanatic
 
Second Quarter 2013 Investor Presentation
Second Quarter 2013 Investor PresentationSecond Quarter 2013 Investor Presentation
Second Quarter 2013 Investor Presentation
 
Reebok the sport of fitness has arrived
Reebok   the sport of fitness has arrivedReebok   the sport of fitness has arrived
Reebok the sport of fitness has arrived
 
Linking words
Linking wordsLinking words
Linking words
 
Decline of the Roman Republic
Decline of the Roman RepublicDecline of the Roman Republic
Decline of the Roman Republic
 
Ozel ders-izmir
Ozel ders-izmirOzel ders-izmir
Ozel ders-izmir
 
Emperor penguins in_antarctica
Emperor penguins in_antarcticaEmperor penguins in_antarctica
Emperor penguins in_antarctica
 
Madkour and zinhome
Madkour and zinhomeMadkour and zinhome
Madkour and zinhome
 
الطريق اتجاه واحد النبوءه - الحقيقه - One way -
الطريق اتجاه واحد   النبوءه - الحقيقه - One way -الطريق اتجاه واحد   النبوءه - الحقيقه - One way -
الطريق اتجاه واحد النبوءه - الحقيقه - One way -
 
женщины
женщиныженщины
женщины
 

Similar to HIV Highlights From Seattle

Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
hivlifeinfo
 
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
hivlifeinfo
 
First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013
hivlifeinfo
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
hivlifeinfo
 
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Hivlife Info
 
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
hivlifeinfo
 
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
hivlifeinfo
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Hivlife Info
 
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
hivlifeinfo
 
The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...
hivlifeinfo
 
The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...
Hivlife Info
 
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
hivlifeinfo
 
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
hivlifeinfo
 
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
hivlifeinfo
 
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
hivlifeinfo
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Hivlife Info
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
hivlifeinfo
 
Clinical Impact of New Data From AIDS 2020
Clinical Impact of New Data From AIDS 2020Clinical Impact of New Data From AIDS 2020
Clinical Impact of New Data From AIDS 2020
hivlifeinfo
 
11
1111
11.07.06 Correlacist
11.07.06 Correlacist11.07.06 Correlacist
11.07.06 Correlacist
Flavio Guzmán
 

Similar to HIV Highlights From Seattle (20)

Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
Топ достижений лечения ВИЧ в 2017 г / Top Advances in ART for 2017
 
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...Современное лечение ВИЧ:  индивидуализация стартовой АРТ /Contemporary Manage...
Современное лечение ВИЧ: индивидуализация стартовой АРТ /Contemporary Manage...
 
First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013First and foremost choosing and using first line antiretroviral therapy.2013
First and foremost choosing and using first line antiretroviral therapy.2013
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
 
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
 
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
Fall 2014 HIV Update.Clinical Impact of New Data From ICAAC 2014, IDWeek 2014...
 
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
Современное лечение ВИЧ.Усилить или не усилить : преимущества и недостатки бу...
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
 
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
Оптимизация лечения ВИЧ в 2018 году / HIV Treatment Optimization: 2018
 
The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...
 
The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...The role of integrase inhibitors in first line and later antiretroviral thera...
The role of integrase inhibitors in first line and later antiretroviral thera...
 
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
 
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
Современное лечение и профилактика ВИЧ : передовые стратегии лечения у пациен...
 
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
Key Slides on ART for HIV : Evolving Concepts and Innovative Strategies.2020
 
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
Современное лечение ВИЧ: АРТ у пациентов с сопутствующими заболеваниями.Conte...
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
 
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
Should Integrase Inhibitors Be Your First Choice When Starting HIV Therapy- E...
 
Clinical Impact of New Data From AIDS 2020
Clinical Impact of New Data From AIDS 2020Clinical Impact of New Data From AIDS 2020
Clinical Impact of New Data From AIDS 2020
 
11
1111
11
 
11.07.06 Correlacist
11.07.06 Correlacist11.07.06 Correlacist
11.07.06 Correlacist
 

Recently uploaded

VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
sukaniyasunnu
 
Introduction to Dental Implant for undergraduate student
Introduction to Dental Implant for undergraduate studentIntroduction to Dental Implant for undergraduate student
Introduction to Dental Implant for undergraduate student
Shamsuddin Mahmud
 
CASE PRESENTATION ON ACUTE GASTROENTERITIS.
CASE PRESENTATION ON ACUTE GASTROENTERITIS.CASE PRESENTATION ON ACUTE GASTROENTERITIS.
CASE PRESENTATION ON ACUTE GASTROENTERITIS.
Bhavana
 
Techniques and Principles of Cleaning and Shaping
Techniques and Principles of Cleaning and ShapingTechniques and Principles of Cleaning and Shaping
Techniques and Principles of Cleaning and Shaping
DheerajGupta915466
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
Aloy Okechukwu Ugwu
 
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
Ks doctor
 
Drugs Used in the Treatment of Arrhythmia
Drugs Used in the Treatment of ArrhythmiaDrugs Used in the Treatment of Arrhythmia
Drugs Used in the Treatment of Arrhythmia
Dr. Nikhilkumar Sakle
 
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
rightmanforbloodline
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
Dr. Dheeraj Kumar
 
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
CarriePoppy
 
Health communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptxHealth communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptx
Tina Purnat
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
Dr. vaishali Kadam
 
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
NephroTube - Dr.Gawad
 
MEDICAL PROFESSIONALISM Class of compassionate care
MEDICAL PROFESSIONALISM Class of compassionate careMEDICAL PROFESSIONALISM Class of compassionate care
MEDICAL PROFESSIONALISM Class of compassionate care
Debre Berhan University
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
MedicoseAcademics
 
Ativisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISMAtivisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISM
SaketkumarSrivastava
 
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
MARIALUISADELROGONZL
 
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Aloy Okechukwu Ugwu
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
Niranjan Chavan
 

Recently uploaded (20)

VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
VIP Hyderabad Girls Call Service Hyderabad 0X0000000X Independent Service Ava...
 
Introduction to Dental Implant for undergraduate student
Introduction to Dental Implant for undergraduate studentIntroduction to Dental Implant for undergraduate student
Introduction to Dental Implant for undergraduate student
 
CASE PRESENTATION ON ACUTE GASTROENTERITIS.
CASE PRESENTATION ON ACUTE GASTROENTERITIS.CASE PRESENTATION ON ACUTE GASTROENTERITIS.
CASE PRESENTATION ON ACUTE GASTROENTERITIS.
 
Techniques and Principles of Cleaning and Shaping
Techniques and Principles of Cleaning and ShapingTechniques and Principles of Cleaning and Shaping
Techniques and Principles of Cleaning and Shaping
 
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsxDr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
Dr.Tarik Enaairi - Dermatology - Mastocytosis.ppsx
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
 
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
1130712-肺阻塞照護新趨勢-講師:鄭孟軒社主任-社團法人高雄市醫師公會.pdf
 
Drugs Used in the Treatment of Arrhythmia
Drugs Used in the Treatment of ArrhythmiaDrugs Used in the Treatment of Arrhythmia
Drugs Used in the Treatment of Arrhythmia
 
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
TEST BANK Physical Examination and Health Assessment 9th Edition by Carolyn J...
 
Introduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptxIntroduction to Interventional Radiology.pptx
Introduction to Interventional Radiology.pptx
 
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
2024 07 12 Do you share my autistic traits_ - Google Sheets.pdf
 
Health communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptxHealth communication, AI and health misinformation.pptx
Health communication, AI and health misinformation.pptx
 
Pernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptxPernacious Anamia. payhophysiology..pptx
Pernacious Anamia. payhophysiology..pptx
 
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
Hemodialysis: Chapter 10, AVF and AVG - Complications (Diagnosis and Manageme...
 
MEDICAL PROFESSIONALISM Class of compassionate care
MEDICAL PROFESSIONALISM Class of compassionate careMEDICAL PROFESSIONALISM Class of compassionate care
MEDICAL PROFESSIONALISM Class of compassionate care
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
 
Ativisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISMAtivisha by Saket in Dravyguna BAMS NCISM
Ativisha by Saket in Dravyguna BAMS NCISM
 
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allog...
 
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...Intl J Gynecology   Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
Intl J Gynecology Obste - 2024 - Nwagha - Multidisciplinary approach to obs...
 
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptxOBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
OBSTETRICS SEPSIS - BUNDLE APPROACH.pptx
 

HIV Highlights From Seattle

  • 1. HIV Highlights From Seattle CCO Independent Conference Coverage of the 2012 Conference on Retroviruses and Opportunistic Infections* March 5-8, 2012 Seattle, Washington *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This program is supported by educational grants from Originally posted 3/20/2012 at clinicaloptions.com/ss/Seattle2012
  • 2. HIV Highlights From Seattle clinicaloptions.com/hiv About These Slides  Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent  This abbreviated slideset was posted to SlideShare to publicize the availability of the full slideset. These slides may not be published or posted online without permission from CCO (email permissions@clinicaloptions.com) Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
  • 3. HIV Highlights From Seattle clinicaloptions.com/hiv Faculty Joseph J. Eron, Jr., MD Kimberly Y. Smith, MD, MPH Professor of Medicine and Associate Professor of Medicine Epidemiology Division of Infectious Diseases University of North Carolina Rush University Medical Center School of Medicine Chicago, Illinois Director, AIDS Clinical Trials Unit University of North Carolina Chapel Hill, North Carolina
  • 4. HIV Highlights From Seattle clinicaloptions.com/hiv Faculty Disclosures Joseph J. Eron, Jr., MD, has disclosed that he has received grants for research support from Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Merck, Taimed, and Tobira; has served as a consultant for Argos, Avexa, Bristol-Myers Squibb, Chimerix, Gilead Sciences, GlaxoSmithKline/ViiV, Inhibitex, Kainos Pharmaceutical, LabCorp, Merck, Myriad, Pfizer, Tibotec, Tobira, and Virco Laboratories; and has served on data and safety monitoring boards for Tibotec/Janssen and Vertex. Kimberly Y. Smith, MD, MPH, has disclosed that she has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV.
  • 5. Please review the slide notes for a complete discussion of each study by expert faculty Joseph J. Eron, Jr., MD, and Kimberly Y. Smith, MD, MPH
  • 7. HIV Highlights From Seattle clinicaloptions.com/hiv Elvitegravir/Cobicistat/TDF/FTC vs EFV/TDF/FTC in Treatment-Naive Patients  Multicenter, randomized, double-blinded, active-controlled phase III study Wk 48 Planned follow-up Stratified by primary analysis to Wk 192 baseline HIV-1 RNA > or ≤ 100,000 copies/mL Elvitegravir/Cobicistat/TDF/FTC QD + EFV/TDF/FTC placebo QD HIV-infected (n = 348) treatment-naive patients with HIV-1 RNA ≥ 5000 copies/mL, any CD4+ cell count, CLCR ≥ 70 mL/min EFV/TDF/FTC QD (N = 700) + Elvitegravir/Cobicistat/TDF/FTC placebo QD (n = 352) Sax P, et al. CROI 2012. Abstract 101.
  • 8. HIV Highlights From Seattle clinicaloptions.com/hiv Elvitegravir/Cobicistat Regimen Noninferior to EFV Regimen at Wk 48 100 88 90 84 EVG/COBI/FTC/TDF 84 85 82 (n = 348) 80 EFV/FTC/TDF 60 (n = 352) 40 20 0 Overall HIV-1 RNA HIV-1 RNA ≤ 100,000 c/mL > 100,000 c/mL  Greater CD4+ count increase with EVG/COBI vs EFV: 239 vs 206 cells/mm3 (P = .009)  Among pts with confirmed virologic failure or rebound, resistance detected in 8/14 pts in EVG/COBI arm vs 8/17 patients in EFV arm – Primary integrase mutations and primary NNRTI mutations observed in 7 and 8 patients in EVG/COBI and EFV arms, respectively – All 8 pts in EVG/COBI arm had M184V/I mutation vs 2 pts in EFV arm; 3 and 2 had K65R, respectively Sax P, et al. CROI 2012. Abstract 101.
  • 9. HIV Highlights From Seattle clinicaloptions.com/hiv Safety of Elvitegravir/Cobicistat Regimen vs EFV Regimen  Significantly greater incidence of nausea with EVG/COBI regimen  Significantly greater incidence of sleep disturbance, dizziness, rash with EFV regimen  1.4% of patients discontinued EVG/COBI regimen due to renal abnormalities vs no patients on EFV regimen – Significantly greater increase in median serum creatinine from baseline to Wk 48 in EVG/COBI group: 0.14 vs 0.01 mg/dL (P < .001) – Majority of increase in serum creatinine clearance occurred within 2 wks of starting treatment and progressed minimally over time  Significantly greater increases in total, LDL, and HDL cholesterol from baseline to Wk 48 in EFV vs EVG/COBI groups (all P ≤ .001) Sax P, et al. CROI 2012. Abstract 101.
  • 10. HIV Highlights From Seattle clinicaloptions.com/hiv Elvitegravir/Cobicistat/TDF/FTC vs ATV/RTV + TDF/FTC in Tx-Naive Patients  Multicenter, randomized, double-blinded, active-controlled phase III study Wk 48 Planned follow-up Stratified by primary analysis to Wk 192 baseline HIV-1 RNA > or ≤ 100,000 copies/mL Elvitegravir/Cobicistat/TDF/FTC QD HIV-infected + ATV/RTV + FTC/TDF placebo QD treatment-naive patients, (n = 353) HIV-1 RNA ≥ 5000 copies/mL, any CD4+ cell count, CLCR ≥ 70 mL/min ATV/RTV + TDF/FTC QD (N = 708) + Elvitegravir/Cobicistat/TDF/FTC placebo QD (n = 355) DeJesus E, et al. CROI 2012. Abstract 627.
  • 11. HIV Highlights From Seattle clinicaloptions.com/hiv Elvitegravir/Cobicistat Regimen Noninferior to ATV/RTV Regimen at Wk 48 100 90 93 90 EVG/COBI/FTC/TDF 87 85 82 (n = 353) 80 ATV/RTV + FTC/TDF 60 (n = 355) 40 20 0 Overall HIV-1 RNA HIV-1 RNA ≤ 100,000 c/mL > 100,000 c/mL  Similar CD4+ cell count increases in both study arms at Wk 48  Among pts with confirmed virologic failure or rebound, resistance detected in 5/12 pts in EVG/COBI arm vs 0/8 pts in ATV/RTV arm – 4/5 pts in EVG/COBI arm had M184V/I mutation; 4 had primary integrase mutations DeJesus E, et al. CROI 2012. Abstract 627.
  • 12. HIV Highlights From Seattle clinicaloptions.com/hiv Safety of Elvitegravir/Cobicistat Regimen vs ATV/RTV Regimen  Similar rates of grade 3/4 adverse events between arms: 13% in EVG/ COBI and 14% in ATV/RTV arm – Most common adverse events: diarrhea, nausea  Grade 3/4 hyperbilirubinemia more common in ATV/RTV group: 58% vs 1%  Significantly greater increase in median serum creatinine from baseline to Wk 48 in EVG/COBI group: 0.12 vs 0.08 mg/dL (P < .001) – Majority of increase in serum creatinine clearance occurred within 2 wks of starting treatment and progressed minimally over time  Significantly greater increase in median triglycerides from baseline to Wk 48 in ATV/RTV group: 23 vs 8 mg/dL (P = .006); otherwise no difference in lipid values DeJesus E, et al. CROI 2012. Abstract 627.
  • 13. HIV Highlights From Seattle clinicaloptions.com/hiv SPRING-1: Phase IIb Trial of Dolutegravir vs Efavirenz in Tx-Naive Patients 100 88 < 50 copies/mL (TLOVR) (%)[1] 79 Patients With HIV-1 RNA 78 80 72 60 40 DTG 10 mg QD (n = 53) DTG 25 mg QD (n = 51) DTG 50 mg QD (n = 51) 20 EFV 600 mg (n = 50) 0 BL 4 8 1216 20 24 32 40 48 60 72 84 96 Wk  Comparable efficacy among arms  No cases of virologic failure in 50-mg arm  Minimal variations in serum creatinine observed across treatment arms – Alterations did not progress over time – Previous study showed DTG had no effect on glomerular filtration rate by iohexol clearance[2] 1. Stellbrink HJ, et al. CROI 2012. Abstract 102LB. 2. Koteff J, et al. ICAAC 2011. Abstract A1-1728.
  • 14. HIV Highlights From Seattle clinicaloptions.com/hiv GS-7340: Antiviral Activity of Novel Prodrug of Tenofovir  Lower TDF plasma concentrations, higher intracellular concentrations obtained with GS-7340 vs TDF – Hypothesized that this may result in greater efficacy, reduced toxicity  Previous study evaluated higher doses of GS-7340: 50 mg and 150 mg[1] 10 days TDF 300 mg QD (n = 6) HIV-infected GS-7340 8 mg QD treatment-naive or -experienced patients with no genotypic (n = 9) resistance to TDF, GS-7340 25 mg QD HIV-1 RNA ≥ 2000 copies/mL, (n = 8) CD4+ count ≥ 200 cells/mm3[2] GS-7340 40 mg QD (N = 38) (n = 8) GS-7340 Placebo QD (n = 7) 1. Markowitz M, et al. CROI 2011. Abstract 152LB. 2. Ruane PJ, et al. CROI 2012. Abstract 103.
  • 15. HIV Highlights From Seattle clinicaloptions.com/hiv Greater Antiviral Activity of GS-7340 25 mg and 40 mg vs TDF Dosing 0.5 Placebo (n = 7) 0.0 TDF 300 mg (n = 6) GS-7340 8 mg (n = 9) -0.5 GS-7340 25 mg (n = 8) GS-7340 40 mg (n = 8) -1.0 -1.5 -2.0 0 10 20 Day  Higher intracellular tenofovir diphosphate levels and lower circulating plasma tenofovir levels with GS-7340 vs TDF Ruane PJ, et al. CROI 2012. Abstract 103.
  • 16. For the rest of this presentation download the full PowerPoint slideset for self-study or use in your own educational presentations at: clinicaloptions.com/ss/seattle2012 Go Online for More CCO Coverage of CROI 2012: Capsule Summaries of key data from the meeting & CME-certified slideset incorporating a discussion among 2 expert faculty exploring the clinical implications of each study More ways to connect with CCO:

Editor's Notes

  1. Please view the PowerPoint notes to review the faculty commentary on each slide.
  2. Please review the slide notes for a complete discussion of each study by expert faculty Joseph J. Eron, Jr., MD, and Kimberly Y. Smith, MD, MPH
  3. CLcr, creatinine clearance; EFV, efavirenz; FTC, emtricitabine; QD, once daily; TDF, tenofovir.   Kimberly Y. Smith, MD, MPH: This randomized trial compared the once-daily, single-tablet coformulation of elvitegravir/cobicistat/tenofovir/emtricitabine with fixed-dose efavirenz/tenofovir/emtricitabine in treatment-naive patients with HIV-1 RNA levels ≥ 5000 copies/mL. Mean CD4+ cell counts at baseline were 382-391 cells/mm3 and only 12% to 14% of patients had CD4+ cell counts ≤ 200 cells/mm3.   Joseph J. Eron, Jr., MD: Another important feature of the population enrolled in this study is that it was predominantly male, with women constituting only 10% to 12% of each treatment arm. In addition, study participants were required to have a creatinine clearance rate ≥ 70 mL/min, which is higher than other large, comparative studies and is in part because cobicistat has an effect on creatinine secretion. Creatinine levels increase modestly in most patients who initiate cobicistat, not because of impaired glomerular filtration, but rather because of reduced proximal tubular creatinine secretion. [1,2]   References 1. German P, Liu C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, Illinois. Abstract H2-804. 2. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray AS. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, Illinois. Abstract A1-1724.
  4. COBI, cobicistat; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; TDF, tenofovir. Kimberly Y. Smith, MD, MPH: Similar rates of HIV-1 RNA &lt; 50 copies/mL at Week 48 were observed with elvitegravir/cobicistat/tenofovir/emtricitabine vs fixed-dose efavirenz/tenofovir/emtricitabine. An important finding is that although the efficacy rate was slightly lower among patients with baseline HIV-1 RNA &gt; 100,000 copies/mL vs patients with baseline HIV-1 RNA ≤ 100,000 copies/mL in the elvitegravir/cobicistat/tenofovir/emtricitabine arm, the difference was not clinically relevant. However, another key point regarding efficacy in patient subgroups is the impact of baseline CD4+ cell count. In the elvitegravir/cobicistat/tenofovir/emtricitabine arm, 83% of patients with baseline CD4+ cell counts ≤ 350 cells/mm3 achieved HIV-1 RNA &lt; 50 copies/mL at Week 48 vs 91% of patients with baseline CD4+ cell counts &gt; 350 cells/mm3. However, it is useful to reiterate that the proportion of patients with baseline CD4+ cell counts ≤ 200 cells/mm3 was low, and therefore, we still have only limited information regarding the efficacy of this regimen among patients with lower CD4+ cell counts and high HIV-1 RNA at baseline.   Joseph J. Eron, Jr., MD: I agree with that assessment. Another notable result from this study is that primary resistance to the anchor drug, the integrase inhibitor elvitegravir or the NNRTI efavirenz, emerged in nearly the same number of patients: 7 and 8, respectively. Therefore, although both of these drugs are generally considered to have a low genetic barrier to resistance, only 2% of the total population developed either an integrase inhibitor resistance mutation on elvitegravir or an NNRTI resistance mutation on efavirenz. One difference between the 2 regimens was that if a patient developed resistance on the elvitegravir arm, they were likely to also develop NRTI resistance, whereas NRTI resistance on the efavirenz arm was somewhat less likely. I think that is a potential difference between the 2 treatment regimens, although it is a relatively modest difference given that approximately 350 patients received the drugs in either arm.
  5. COBI, cobicistat; EFV, efavirenz; EVG, elvitegravir; HDL, high-density lipoprotein; LDL, low-density lipoprotein.   Joseph J. Eron, Jr., MD: In terms of safety, nausea occurred more frequently with elvitegravir/cobicistat/tenofovir/emtricitabine vs efavirenz/tenofovir/emtricitabine. It is interesting to note that most of the nausea was grade 1; it will be important to determine if that level of nausea will be bothersome to patients in clinical practice. The efavirenz-associated adverse effects were similar to previous trials, and only 4% to 5% of patients had to discontinue either treatment regimen as a result of toxicity. However, 4 patients discontinued the elvitegravir/cobicistat regimen because of renal dysfunction. One of the patients had a modest increase in creatinine. The other 3 patients had changes in renal function consistent with a tenofovir effect.   Kimberly Y. Smith, MD, MPH: A clinical point that might be useful for physicians is that the change in creatinine occurred early, within approximately the first 2 weeks, and was not progressive. Physicians who have extensive experience administering tenofovir know that there tends to be a progressive, stepwise increase in creatinine levels that does not plateau. Clinicians will be looking for ways to distinguish between elvitegravir/cobicistat and tenofovir toxicity, and the pattern of change in creatinine might be one difference, as well as the tell‑tale signs of tenofovir toxicity, including glucose in the urine, protein in the urine, and so on. Any clues that can be obtained from this study to assist with determining the source of changes in creatinine levels when they occur will be valuable.   Joseph J. Eron, Jr., MD: Finally, an unanticipated outcome of this study was that the cobicistat-containing regimen did not seem to have a strong effect on triglyceride levels. I expected that cobicistat might result in elevated triglyceride levels, similar to ritonavir, but this was not the case.   Kimberly Y. Smith, MD, MPH: I agree that the lipid effect of cobicistat appears to be more distinct from ritonavir than expected.
  6. ATV, atazanavir; CLcr, creatinine clearance; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; QD, once daily; RTV, ritonavir; TDF, tenofovir; tx, treatment.   Kimberly Y. Smith, MD, MPH: The next study used a similar study design to compare elvitegravir/cobicistat/tenofovir/emtricitabine with atazanavir/ritonavir plus tenofovir/emtricitabine in treatment-naive patients with HIV-1 RNA levels ≥ 5000 copies/mL. As with the previously discussed trial, study participants were required to have a creatinine clearance rate ≥ 70 mL/min. Mean baseline CD4+ cell counts were 364-375 cells/mm3, and 11% to 15% of patients had CD4+ cell counts ≤ 200 cells/mm3 at baseline.
  7. ATV, atazanavir; COBI, cobicistat; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; RTV, ritonavir; TDF, tenofovir.   Kimberly Y. Smith, MD, MPH: The results demonstrated comparable virologic response at Week 48 with both regimens. There was no clinically meaningful reduction in activity of the elvitegravir regimen among patients with higher vs lower baseline HIV-1 RNA levels, although the difference between these subgroups was slightly larger than that observed in the previously discussed elvitegravir study.   Joseph J. Eron, Jr., MD: In addition, similar to most studies of boosted PI regimens in treatment-naive patients, no resistance mutations emerged among patients receiving atazanavir/ritonavir who experienced virologic failure or rebound. However, 5 patients in the elvitegravir arm developed drug resistance, including primary integrase inhibitor–resistance mutations in 4 patients and M184V/I in 4 patients; it is notable that these values represent a small percentage of the overall population.   Kimberly Y. Smith, MD, MPH: It is also worth noting that, in both randomized comparative elvitegravir/cobicistat/tenofovir/ emtricitabine studies, the control arm performed very well; therefore, the fact that the elvitegravir-based regimen was able to perform as well as the control arm reflects very favorably on its efficacy.
  8. ATV, atazanavir; COBI, cobicistat; EVG, elvitegravir; RTV, ritonavir.   Joseph J. Eron, Jr., MD: The safety analysis demonstrated similar rates of diarrhea and nausea between the 2 treatment arms. As would be expected, grade 3/4 hyperbilirubinemia occurred much more frequently in the atazanavir arm vs the elvitegravir arm. As with the previously discussed elvitegravir trial, serum creatinine increases were higher with elvitegravir-based treatment vs the control arm. Similar to the trend Dr. Smith noted in the previous trial, creatinine increases occurred very early during treatment, with the majority of the increase occurring during the first 2-4 weeks of therapy, which became relatively stable thereafter. This observation is useful to clinicians when planning a monitoring strategy. I usually schedule a follow-up visit with patients after approximately 4 weeks of treatment to assess response and tolerability. When the elvitegravir/cobicistat/tenofovir/emtricitabine pill becomes available, I will obtain creatinine levels at 4 weeks in patients who I start on this therapy and use the 4-week value as a new baseline value.
  9. DTG, dolutegravir; EFV, efavirenz; tx, treatment; TLOVR, time to loss of virologic response.   Joseph J. Eron, Jr., MD: This slide depicts the results of a phase IIb study investigating another integrase inhibitor, dolutegravir, vs efavirenz in treatment-naive patients. It is important to underscore that each study arm included only approximately 50 patients. In total, 153 patients were randomized to 1 of 3 dolutegravir doses—10 mg, 25 mg, or 50 mg once daily—each administered in combination with 2 NRTIs.   The results showed that dolutegravir is very potent, with virologic efficacy similar to efavirenz. No cases of virologic failure occurred in the dolutegravir 50-mg/day dosing arm, and there was no emergence of integrase resistance mutations in any of the 3 dolutegravir treatment arms. Only 1 patient in the efavirenz arm experienced protocol-defined virologic failure, and this patient did not have evidence of NNRTI resistance; overall, therefore, the study population appears to have achieved a high level of adherence. In addition, similar to elvitegravir, dolutegravir was associated with small changes in mean serum creatinine. These changes are likely related to mild inhibition of tubular creatinine secretion, as a previous study demonstrated that dolutegravir had no effect on glomerular filtration rate measured by iohexol clearance. Based on the results of the phase IIb analysis, the 50-mg once-daily dose of dolutegravir was selected for ongoing clinical development and phase III testing.   Kimberly Y. Smith, MD, MPH: I agree that this study demonstrated dolutegravir to be very potent. It is important to recognize that dolutegravir is a once-daily integrase inhibitor that does not require boosting, unlike elvitegravir. It seemed to be well tolerated, with the exception of the change in creatinine that has been discussed in some detail. These data are very positive, and we look forward to the results of the phase III studies.
  10. QD, once daily; TDF, tenofovir.   Joseph J. Eron, Jr., MD: The study shown on this slide evaluated the efficacy of GS-7340, a novel prodrug of tenofovir. When tenofovir disoproxil fumarate is administered, tenofovir is found circulating in the plasma; however, intracellular tenofovir diphosphate is the active drug. Because GS-7340 is rapidly taken up by cells, high intracellular concentrations of tenofovir diphosphate are achieved with relatively low circulating plasma concentrations of tenofovir. Therefore, it is hypothesized—although not yet proven—that GS‑7340 may have less tenofovir-associated toxicity, that is, less bone and renal toxicity. The other important feature of this agent is that the lower dosing level reduces the milligram footprint. Therefore, it will be easier to coformulate GS-7340 with other drugs into a single tablet. In fact, a single-tablet regimen consisting of darunavir/cobicistat/emtricitabine/GS-7340 has already been coformulated and is being studied in a planned phase II study. [1]   Kimberly Y. Smith, MD, MPH: This phase II dose-ranging trial follows a previous study presented 1 year ago that examined higher doses of this agent and found that even the lowest dose was associated with very high intracellular drug levels. The current study assessed the extent to which the dose could be reduced and still maintain virologic efficacy. Reference 1. ClinicalTrials.gov. Safety and efficacy of darunavir/cobicistat/emtricitabine/GS-7340 single tablet regimen vs cobicistat-boosted darunavir plus emtricitabine/tenofovir disoproxil fumarate fixed dose combination in HIV-1 infected, antiretroviral treatment naive adults. Available at: http://clinicaltrials.gov/ct2/show/NCT01565850. Accessed April 23, 2012.  
  11. TDF, tenofovir.   Joseph J. Eron, Jr., MD: This slide shows that even at the relatively low dose of 25 mg/day, the median reduction in HIV-1 RNA was approximately 1.5 log10 copies/mL corresponding to an approximate 30-fold decrease in HIV-1 RNA levels over a 10- or 11-day period.   Kimberly Y. Smith, MD, MPH: I would underscore the point that it is not yet known if the toxicity profile of this agent differs from tenofovir disoproxil fumarate. Theoretically, it seems logical that toxicity should be reduced because plasma drug levels are lower, but that hypothesis will need to be supported with clinical data.